BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR 101.70
+6.60 (6.94%)
At close: Aug 21, 2026
BioNTech SE Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,650 | 2,870 | 2,751 | 3,819 | 17,311 | 18,977 |
Revenue Growth | -7.94% | 4.32% | -27.96% | -77.94% | -8.78% | 3834.63% |
Gross Profit Gross Profit Growth | 2,031 | 2,259 | 2,210 | 3,219 | 14,316 | 16,065 |
Operating Income Operating Income Growth | -1,817 | -1,267 | -1,286 | 971.8 | 11,918 | 14,847 |
Net Income Net Income Growth | -1,686 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Earnings Per Share EPS Growth | -6.80 | -4.70 | -2.77 | 3.83 | 37.77 | 39.63 |
EPS Growth | - | - | - | -89.86% | -4.69% | 65950.00% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
COVID-19 Vaccine COVID-19 Vaccine Growth | 1,828 | 1,995 | 2,432 | 3,776 | 17,145 |
Out-Licensing Out-Licensing Growth | - | 613 | - | - | - |
Other Sales Other Sales Growth | 209.2 | 261.6 | 319 | 42.8 | 165.4 |
Revenue (Total) Revenue (Total) Growth | 2,426 | 3,055 | 2,892 | 3,924 | 17,311 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 13,464 | 13,741 | 15,844 | 16,549 | 14,065 | 2,074 |
Total Debt Total Debt Growth | 316.1 | 267.4 | 254.2 | 219.1 | 212.2 | 301.5 |
Net Cash (Debt) Net Cash Growth | 13,148 | 13,473 | 15,590 | 16,330 | 13,852 | 1,773 |
Net Cash Growth | -1.62% | -13.58% | -4.53% | 17.88% | 681.38% | 60.10% |
Net Cash Per Share Net Cash Per Share Growth | 53.04 | 55.74 | 64.85 | 67.28 | 55.45 | 6.83 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 679.7 | 456 | 207.7 | 5,371 | 13,577 | 889.7 |
Capital Expenditures CapEx Growth | -210.5 | -175.1 | -286.5 | -250.1 | -329.2 | -127.5 |
Free Cash Flow Free Cash Flow Growth | 469.2 | 280.9 | -78.8 | 5,121 | 13,248 | 762.2 |
Free Cash Flow Growth | - | - | - | -61.34% | 1638.15% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 76.62% | 78.70% | 80.32% | 84.29% | 82.70% | 84.66% |
Operating Margin | -68.57% | -44.14% | -46.73% | 25.45% | 68.85% | 78.23% |
Pretax Margin | -61.49% | -36.61% | -24.63% | 31.06% | 74.83% | 79.29% |
Profit Margin | -63.64% | -39.59% | -24.18% | 24.36% | 54.50% | 54.24% |
FCF Margin | 17.71% | 9.79% | -2.86% | 134.10% | 76.53% | 4.02% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 24.40 | 3.62 | 5.32 |
P/FCF Ratio | 53.46 | 69.41 | - | 4.43 | 2.58 | 71.83 |
PS Ratio | 9.47 | 6.79 | 9.59 | 5.94 | 1.97 | 2.89 |